Nature最新综述 | 抗癌突破口——CD47抗体类免疫疗法(7)

2019-11-22  未知 admin

[13] Weiskopf, K. et al. Engineered SIRPα variants as immunotherapeutic adjuvants to anticancer antibodies. Science(2013).

[14] Lin, G. H. Y. et al. TTI-621 (SIRPαFc), a CD47-blocking cancer immunotherapeutic, triggers phagocytosis of lymphoma cells by multiple polarized macrophage subsets. PLOS ONE (2017).

[15] Petrova, P. S. et al. TTI-621 (SIRPαFc): a CD47-blocking innate immune checkpoint inhibitor with broad antitumor activity and minimal erythrocyte binding. Clin. Cancer Res. (2017).

[16] Betancur, P. A. et al. A CD47-associated super-enhancer links pro-inflammatory signalling to CD47 upregulation in breast cancer. Nat. Commun. (2017).

[17] Chao, M. P. et al. Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma. Cell (2010).

[18] Ngo, M. et al. Antibody therapy targetingCD47 and CD271 effectively suppresses melanoma metastasis in patient-derived xenografts. Cell Rep. (2016).

[19] Weiskopf, K. et al. CD47-blocking immunotherapies stimulate macrophage-mediated destruction of small-cell lung cancer. J. Clin. Invest. (2016).

[20] Zhang, M. et al. Anti-CD47 treatment stimulates phagocytosis of glioblastoma by M1 and M2 polarized macrophages andpromotes M1 polarized macrophages in vivo. PLOS ONE (2016).

[21] Bian, Z. et al. CD47–SIRPα interaction and IL-10 constrain inflammation-induced macrophage phagocytosis of healthy self-cells. Proc. Natl Acad. Sci. (2016).

[22] Liu, X. et al. Dual targeting of innateand adaptive checkpoints on tumor cells limits immune evasion. Cell Rep. (2018).

[23] Advani, R. et al. CD47 blockade by Hu5F9-G4 and rituximab in non-Hodgkin’s lymphoma. N. Engl. J. Med. (2018).

[24] Johnson, L. D. S. et al. Targeting CD47 in Sezary syndrome with SIRPαFc. Blood Adv. (2019).